Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012

Clinical Infectious Diseases

Volumn 60, Issue 6, 2015, Pages 959-965

  McKenney, Jennie ^a   Bauman, Sean ^b   Neary, Brandon ^b   Detels, Roger ^a   French, Audrey ^c   Margolick, Joseph ^d   Doherty, Brian ^b   Klausner, Jeffrey D ^a,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b IMMY   (United States)

^c Jr Hospital of Cook County   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cryptococcal meningitis; HIV AIDS; Prevalence; Screening

Indexed keywords

FUNGUS ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS PATIENT; ARTICLE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; CRYPTOCOCCAL MENINGITIS; DISEASE COURSE; EARLY DIAGNOSIS; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; SCREENING; SERUM; STORAGE; SURVIVAL; UNITED STATES; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; COST BENEFIT ANALYSIS; CRYPTOCOCCOSIS; FILOBASIDIELLA; IMMUNOLOGY; ISOLATION AND PURIFICATION; MENINGITIS, CRYPTOCOCCAL; MULTICENTER STUDY; TIME; YOUNG ADULT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIGENS, FUNGAL; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; COST-BENEFIT ANALYSIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; FEMALE; HUMANS; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; PREVALENCE; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84936076898     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu937     Document Type: Article

References (39)

1. Alemu A, Kempker R, Tenna A, et al. High prevalence of cryptococcal antigenemia among HIV-infected patient receiving antiretroviral therapy in Ethiopia. PLoS One 2013; 8:1-6.
2. Meyer A, Kendi C, Penner J, et al. The impact of routine cryptococcal antigen screening on survival among HIV-infected individuals with advanced immunosuppression in Kenya. Trop Med Int Health 2013; 18:495-505.
3. Warkentien T, Crum-Cianflone NF. An update on Cryptococcus among HIV-infected patients. Int J STD AIDS 2010; 21:679-84.
4. Meya D, Manabe Y, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count <= 100 cells/l who start HIV therapy in resource-limited settings. Clin Infect Dis 2010; 51:448-55.
5. Pongsai P, Atamasirikul K, Sungkanuparph S. The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts. J Infect 2010; 60:474-7.
6. Park B,Wannemuehler K, Marston B, et al. Estimation of current global burden of cryptococcal meningitis among persons living with HIV/ AIDS. AIDS 2009; 23:525-30.
7. Jarvis J, Harrison T, Lawn S, et al. Cost-effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLoS One 2013; 8:1-10.
8. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviralnaive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45:526.
9. Jarvis J, Meintjes G, Harrison T. Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa. J Infect 2010; 60:496-8.
10. Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Uganda patients with AIDS. Clin Infect Dis 1998; 26:1362-6.
11. Kambugu A, Meya D, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of high active antiretroviral therapy. Clin Infect Dis 2008; 46:1694-701.
12. Jarvis J, Lawn S, Vogt M, et al. Screening for cryptococcal antigenemia in patients accessing antiretroviral treatment program in South Africa. Clin Infect Dis 2009; 48:856-61.
13. Holmquist L, Russo A, Elixhauser A. Meningitis-related hospitalizations in the United States, 2006. Statistical brief 57, Healthcare and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality, 2008.
14. Pyrogos V, Sietz A, Steiner C, et al. Epidemiology of cryptococcal meningitis in the US: 1997-2009. PLoS One 2013; 8:e56269.
15. Rajasingham R, Meya D, Boulware D. Integrating cryptococcal antigen screening and preemptive treatment into routine HIV care. J Acquir Immune Defic Syndr 2012; 59:85-91.
16. French N, Gray K,Watera C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16:1031-8.
17. Hajjeh R, Conn L, Stephens D, et al. Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. J Infect Dis 1999; 179:449-54.
18. Liechty C, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007; 12:929-35.
19. World Health Organization. Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents, and children. Geneva, Switzerland: WHO, 2011. Available at: http://whqlibdoc.who.int/publications/2011/9789241502979-eng.pdf. Accessed January 2014.
20. Aberg J, Gallant J, Ghanem K, et al. Primary care guidelines for management of persons infected with HIV: 2013 updated by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2013; 1-34.
21. Rajasingham R, Boulware D. Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcl. Clin Infect Dis 2012; 55:1742-4.
22. Jarvis J, Lawn S, Wood R, Harrison T. Cryptococcal antigen screening for patients initiating antiretroviral therapy: time for action. Clin Infect Dis 2010; 51:1463-5.
23. Multicenter AIDS Cohort Study. Available at: http://www.statepi.jhsph. edu/macs/history.html. Accessed October 2013.
24. Bacon M, Wyl V, Alden C, et al. The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol 2005; 12:1013-9.
25. Lindsley M, Mekha N, Baggett H, et al. Evaluation of newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis 2011; 53:321-5.
26. Jarvis J, Percival A, Bauman S, et al. Evaluation of a novel point-ofcare cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 2011; 53:1019-23.
27. IMMY, Inc. Package insert for cryptococcal antigen lateral flow assay. Available at: http://www.immy.com/wp-content/uploads/2013/02/ MSDS-CR2003.pdf. Accessed January 2014.
28. Peterson M, Deddens J. A comparison of two methods for estimating prevalence ratios. BMC Med Res Methodol 2008; 8:1-9.
29. Deddens J, Peterson M. Approaches for estimating prevalence ratios. Occup Environ Med 2008; 65:501-6.
30. Coutinho L, Scazufca M, Menezes P. Methods for estimating prevalence ratios in cross-sectional studies. Revista de Salude Publica 2008; 42:1-6.
31. Behrens T, Taeger D, Wellman J, Keil U. Different methods to calculate effect estimates in cross-sectional studies. Methods Inf Med 2004; 43:505-9.
32. Barros A, Hirakata V. Alternatives for logistic regression in crosssectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 2003; 3:1-13.
33. National Institute for Communicable Diseases, South Africa. Monthly surveillance report: January 1-31, 2014. Available at: http://www.nicd. ac.za/assets/files/Monthly%20NICD%20Surveillance%20Report%20-% 20January%202013.pdf. Accessed March 2014.
34. Oursler K,Moore R, Chaisson R. Risk factors for cryptococcal meningitis in HIV-infected patients. AIDS Res Hum Retroviruses 1999; 15:625-31.
35. Micol D, Lortholary O, Sar B, et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIVinfected patients. J Acquir Immune Defic Syndr 2007; 45:555-9.
36. AIDS.gov. Opportunistic infections. Available at: http://aids.gov/hivaids-basics/staying-healthy-with-hiv-aids/potential-related-healthproblems/ opportunistic-infections/. Accessed February 2014.
37. Lomborg B. Rethink HIV: smarter ways to invest in ending HIV in sub-Saharan Africa. Cambridge, UK: Cambridge University Press, 2012.
38. Cohen D, Wu S, Farley T. Comparing the cost-effectiveness of HIV prevention interventions. J Acquir Immune Defic Syndr 2004; 37: 1404-14.
39. Boulware D, Rolfes M, Rajasingham R, et al. Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast. Emerg Infect Dis 2014; 20:43-53.